S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Something is Coming for America's Top Stock (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Laser breakthrough could send stock soaring 2,467% (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Laser breakthrough could send stock soaring 2,467% (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Something is Coming for America's Top Stock (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Laser breakthrough could send stock soaring 2,467% (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Laser breakthrough could send stock soaring 2,467% (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Something is Coming for America's Top Stock (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Laser breakthrough could send stock soaring 2,467% (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Laser breakthrough could send stock soaring 2,467% (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Something is Coming for America's Top Stock (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Laser breakthrough could send stock soaring 2,467% (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Laser breakthrough could send stock soaring 2,467% (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
NASDAQ:MIRM

Mirum Pharmaceuticals (MIRM) Stock Forecast, Price & News

$30.72
-1.20 (-3.76%)
(As of 09/22/2023 ET)
Compare
Today's Range
$30.69
$32.12
50-Day Range
$24.63
$32.85
52-Week Range
$17.32
$33.39
Volume
296,142 shs
Average Volume
713,889 shs
Market Capitalization
$1.18 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$53.33

Mirum Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.20 Rating Score
Upside/​Downside
73.6% Upside
$53.33 Price Target
Short Interest
Bearish
20.15% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.69
Upright™ Environmental Score
News Sentiment
0.33mentions of Mirum Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$4.32 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.41) to $1.03 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Medical Sector

296th out of 965 stocks

Pharmaceutical Preparations Industry

123rd out of 456 stocks


MIRM stock logo

About Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.

MIRM Price History

MIRM Stock News Headlines

WARNING: Mandatory U.S. Dollar Recall is Weeks Away
If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.
Mirum Pharmaceuticals' (MIRM) Buy Rating Reaffirmed at HC Wainwright
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
Analyst Ratings for Mirum Pharmaceuticals
See More Headlines
Receive MIRM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MIRM Company Calendar

Last Earnings
8/03/2023
Today
9/24/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MIRM
Fax
N/A
Employees
213
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$53.33
High Stock Price Forecast
$84.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+73.6%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
5 Analysts

Profitability

Net Income
$-135,660,000.00
Net Margins
-152.27%
Pretax Margin
-151.70%

Debt

Sales & Book Value

Annual Sales
$77.06 million
Book Value
$3.85 per share

Miscellaneous

Free Float
29,084,000
Market Cap
$1.18 billion
Optionable
Not Optionable
Beta
1.25

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Christopher PeetzMr. Christopher Peetz (Age 44)
    Pres, CEO & Director
    Comp: $1.09M
  • Mr. Peter Radovich M.B.A. (Age 45)
    Ph.D., Chief Operating Officer
    Comp: $732.15k
  • Dr. Pamela Vig Ph.D. (Age 52)
    Head of R&D
    Comp: $678.2k
  • Ms. Lara Longpre MBA (Age 53)
    MSC, Chief Devel. Officer
    Comp: $678.2k
  • Jolanda Howe
    Sr. VP & Global Controller
  • Andrew McKibben
    VP of Investor Relations and Fin.
  • Mr. Paul K. Ross
    Chief Compliance Officer
  • Ms. Erin Campany (Age 55)
    Sr. VP of HR
  • Dr. Ian Clements Ph.D. (Age 54)
    Consultant
  • Ms. Vinita P. Kumar
    Sr. vice Pres of Quality













MIRM Stock - Frequently Asked Questions

Should I buy or sell Mirum Pharmaceuticals stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mirum Pharmaceuticals in the last twelve months. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MIRM shares.
View MIRM analyst ratings
or view top-rated stocks.

What is Mirum Pharmaceuticals' stock price forecast for 2023?

5 brokerages have issued 1-year price targets for Mirum Pharmaceuticals' stock. Their MIRM share price forecasts range from $30.00 to $84.00. On average, they expect the company's stock price to reach $53.33 in the next twelve months. This suggests a possible upside of 73.6% from the stock's current price.
View analysts price targets for MIRM
or view top-rated stocks among Wall Street analysts.

How have MIRM shares performed in 2023?

Mirum Pharmaceuticals' stock was trading at $19.50 on January 1st, 2023. Since then, MIRM stock has increased by 57.5% and is now trading at $30.72.
View the best growth stocks for 2023 here
.

When is Mirum Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our MIRM earnings forecast
.

How were Mirum Pharmaceuticals' earnings last quarter?

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) issued its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.92) EPS for the quarter, missing analysts' consensus estimates of ($0.81) by $0.11. The business had revenue of $37.50 million for the quarter, compared to analyst estimates of $30 million. Mirum Pharmaceuticals had a negative trailing twelve-month return on equity of 103.59% and a negative net margin of 152.27%.

What ETFs hold Mirum Pharmaceuticals' stock?

ETFs with the largest weight of Mirum Pharmaceuticals (NASDAQ:MIRM) stock in their portfolio include Simplify Propel Opportunities ETF (SURI).Virtus LifeSci Biotech Products ETF (BBP).

What other stocks do shareholders of Mirum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirum Pharmaceuticals investors own include Pfizer (PFE), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Vaxart (VXRT), Advanced Micro Devices (AMD), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), Trevena (TRVN), VBI Vaccines (VBIV) and Dynavax Technologies (DVAX).

When did Mirum Pharmaceuticals IPO?

(MIRM) raised $75 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Evercore ISI and Guggenheim Securities acted as the underwriters for the IPO and Raymond James and Roth Capital Partners were co-managers.

What is Mirum Pharmaceuticals' stock symbol?

Mirum Pharmaceuticals trades on the NASDAQ under the ticker symbol "MIRM."

Who are Mirum Pharmaceuticals' major shareholders?

Mirum Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Eventide Asset Management LLC (9.03%), BlackRock Inc. (5.30%), Rock Springs Capital Management LP (4.75%), State Street Corp (3.90%), Cadian Capital Management LP (3.30%) and Polar Capital Holdings Plc (2.42%). Insiders that own company stock include Christopher Peetz, Eric Bjerkholt, Ian Clements, James E Flynn, John A Maurer, Jolanda Howe, Lara Longpre, Michael G Grey, Niall O'donnell, Pamela Vig, Patrick J Heron and Peter Radovich.
View institutional ownership trends
.

How do I buy shares of Mirum Pharmaceuticals?

Shares of MIRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mirum Pharmaceuticals' stock price today?

One share of MIRM stock can currently be purchased for approximately $30.72.

How much money does Mirum Pharmaceuticals make?

Mirum Pharmaceuticals (NASDAQ:MIRM) has a market capitalization of $1.18 billion and generates $77.06 million in revenue each year. The company earns $-135,660,000.00 in net income (profit) each year or ($4.75) on an earnings per share basis.

How many employees does Mirum Pharmaceuticals have?

The company employs 213 workers across the globe.

How can I contact Mirum Pharmaceuticals?

Mirum Pharmaceuticals' mailing address is 950 TOWER LANE SUITE 1050, FOSTER CITY CA, 94404. The official website for the company is mirumpharma.com. The company can be reached via phone at (650) 667-4085 or via email at ir@mirumpharma.com.

This page (NASDAQ:MIRM) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -